Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (620)	12/15/2005 4:20:19 PM
From: nigel bates	of 933

NeuTec Pharma completes patient recruitment in breast cancer clinical trial using lead drug Mycograb ® 6 December 2005 – Manchester, UK: NeuTec Pharma plc (“NeuTec”) announces that patient recruitment in its clinical study in breast cancer patients has been completed ahead of schedule. The phase Ib, pharmacokinetic, multi-centre, open label study is evaluating the safety and efficacy of Mycograb ® administered in combination with Docetaxel in metastatic or recurrent breast cancer patients. The primary objective of the study is to observe the safety and tolerability of Mycograb ® administered in combination with current gold standard therapy. The secondary objective of the study is to monitor the response rate of the target tumours and overall survival and progression-free survival through 7 months post treatment. It is too early at this stage to comment upon results from the study; however, an update will be given with the Interim Results for the period ended 31 December 2005 in March 2006. Breast cancer continues to be a major cause of mortality and morbidity worldwide. Currently there is no curative therapy for metastatic breast cancer, despite early diagnosis, and the five year survival rate for advanced cancers is only 18%. Professor James Burnie, CEO, commented “We are pleased to have completed patient recruitment so promptly and look forward to reporting results next year. This trial represents an exciting next stage in exploiting Mycograb ®, the human antibody fragment active against extra cellular human and fungal hsp90. Hsp90 has been described as a prime target for combinatorial therapy in cancer and was described recently in Science magazine as ‘the Achilles heel of fungal infection’. In all these diseases a key feature is rapid spread through tissues and we believe that Mycograb ® has the potential to help prevent this.” ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next